2026-07-17
No AI summary for this filing type
View Full Filing (SEC EDGAR)Xeris Biopharma Holdings INC
-$239.0M
Net Activity
Institutions Holding
230
Popularity Rank
#2563
Avg Weight
0.10%
Total Value
$552.5M
230 institutions currently hold XERS, with 141 net buyers and 89 net sellers this quarter.
Institutional Moves (Q1 2026)
Majority Increased
Based on recent trading activity
Net Selling Institutions
89
Net Buying Institutions
141
Top 5 by Value
+$460.5M
Total Buy Value
$214.0M
Total Sell Value
141
Net Buyers
89
Net Sellers
8
Filings (90d)
$2.11M
Total Est. Value
281K shares
Planned Shares
| Filer | Filing Date | Est. Value |
|---|---|---|
| STEVEN PIEPER | 2026-07-07 | $231K |
| STEVEN PIEPER | 2026-07-06 | $144K |
| KEVIN MCCULLOCH | 2026-07-01 | $950K |
| BETH HECHT | 2026-07-01 | $396K |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | 2026-06-04 | $94K |
| HALKUFF DAWN | 2026-06-04 | $118K |
| JOHNSON JOHN | 2026-06-04 | $88K |
| PERSKY MARLA | 2026-06-03 | $93K |
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
No Schedule 13D/13G filings for this ticker
2
Filings (14d)
No AI summary for this filing type
View Full Filing (SEC EDGAR)Xeris Biopharma expanded its board from seven to eight members, appointing Dr. Nerissa Kreher, a seasoned biotech executive with a background as chief medical officer at several companies. CEO John Shannon was named board chair, and Marla S. Persky was designated lead independent director. Dr. Kreher received an initial stock and option award valued at approximately $450,000.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter